Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Applied Therapeutics, Inc. | Executive Chairman, Director | Common Stock | 500K | $2.92M | $5.83 | Dec 19, 2024 | Direct |
Xeris Biopharma Holdings, Inc. | Director | Common Stock | 891K | $1.7M | $1.91 | Jun 5, 2024 | Direct |
Axogen, Inc. | Director | Common Stock | 29K | $223K | $7.68 | Sep 1, 2024 | Direct |
Axogen, Inc. | Director | Employee Stock Option (right to purchase) | 18.2K | $163K | $8.95 | Jun 6, 2024 | Direct |
Axogen, Inc. | Director | Stock Option (right to purchase) | 20.4K | $142K | $6.95 | Sep 1, 2023 | Direct |
Verastem, Inc. | Director | Common Stock | 8.33K | $90.6K | $10.87 | Jun 18, 2024 | Direct |
Axogen, Inc. | Director | Restricted Stock Units | 0 | $0 | $7.68 | Sep 1, 2024 | Direct |
Applied Therapeutics, Inc. | Executive Chairman, Director | Stock Option (Right to Buy) | 1M | Dec 19, 2024 | Direct | ||
Verastem, Inc. | Director | Stock Option (right to buy) | 12.5K | Jun 18, 2024 | Direct | ||
Strongbridge Biopharma plc | Chief Executive Officer, Director | Ordinary Shares | 0 | $2.06 | Oct 5, 2021 | Direct | |
Strongbridge Biopharma plc | Chief Executive Officer, Director | Stock Option (Right to Buy) | 0 | Oct 5, 2021 | Direct | ||
Xeris Biopharma Holdings, Inc. | Director | Stock Option (Right to Buy) | 0 | Mar 18, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
APLT | Applied Therapeutics, Inc. | Dec 19, 2024 | 2 | $0 | 4 | Dec 20, 2024 | Executive Chairman, Director |
APLT | Applied Therapeutics, Inc. | Dec 19, 2024 | 0 | $0 | 3 | Dec 20, 2024 | Executive Chairman, Director |
AXGN | Axogen, Inc. | Sep 1, 2024 | 2 | $0 | 4 | Sep 4, 2024 | Director |
VSTM | Verastem, Inc. | Jun 18, 2024 | 2 | $0 | 4 | Jun 20, 2024 | Director |
AXGN | Axogen, Inc. | Jun 6, 2024 | 2 | $0 | 4 | Jun 10, 2024 | Director |
XERS | Xeris Biopharma Holdings, Inc. | Jun 5, 2024 | 1 | $0 | 4 | Jun 5, 2024 | Director |
XERS | Xeris Biopharma Holdings, Inc. | Mar 18, 2024 | 2 | $429K | 4 | Mar 18, 2024 | Director |
XERS | Xeris Biopharma Holdings, Inc. | Mar 15, 2024 | 1 | $0 | 4 | Apr 1, 2024 | Director |
VSTM | Verastem, Inc. | Mar 11, 2024 | 5 | $0 | 4 | Mar 13, 2024 | Director |
AXGN | Axogen, Inc. | Sep 1, 2023 | 2 | $0 | 4 | Sep 7, 2023 | Director |
XERS | Xeris Biopharma Holdings, Inc. | Jun 7, 2023 | 1 | $0 | 4 | Jun 7, 2023 | Director |
AXGN | Axogen, Inc. | Jun 1, 2023 | 2 | $0 | 4 | Jun 5, 2023 | Director |
VSTM | Verastem, Inc. | May 15, 2023 | 1 | $0 | 4 | May 16, 2023 | Director |
VSTM | Verastem, Inc. | Jun 22, 2022 | 1 | $0 | 4 | Jun 24, 2022 | Director |
XERS | Xeris Biopharma Holdings, Inc. | Jun 8, 2022 | 2 | $0 | 4 | Jun 9, 2022 | Director |
AXGN | Axogen, Inc. | Jun 1, 2022 | 2 | $0 | 4 | Jun 3, 2022 | Director |
VSTM | Verastem, Inc. | May 12, 2022 | 1 | $0 | 4/A | Dec 20, 2022 | Director |
XERS | Xeris Biopharma Holdings, Inc. | Oct 5, 2021 | 8 | $46.6K | 4/A | Oct 8, 2021 | Director |
SBBP | Strongbridge Biopharma plc | Oct 5, 2021 | 2 | $0 | 4 | Oct 6, 2021 | Chief Executive Officer, Director |
XERS | Xeris Biopharma Holdings, Inc. | Oct 5, 2021 | 0 | $0 | 3 | Oct 5, 2021 | Director |
SBBP | Strongbridge Biopharma plc | Oct 1, 2021 | 1 | -$690K | 4 | Oct 5, 2021 | Chief Executive Officer, Director |
AXGN | Axogen, Inc. | Jul 19, 2021 | 1 | $0 | 4 | Jul 21, 2021 | Director |
AXGN | Axogen, Inc. | Jul 19, 2021 | 0 | $0 | 3 | Jul 21, 2021 | Director |
SBBP | Strongbridge Biopharma plc | Jul 2, 2021 | 1 | -$157K | 4 | Jul 7, 2021 | Chief Executive Officer, Director |
VSTM | Verastem, Inc. | Jun 28, 2021 | 1 | $0 | 4 | Jun 30, 2021 | Director |